Medacta Group (XSWX:MOVE) Research & Development: CHF22.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MOVE Medacta Group SA XSWX:MOVE
93 GF Score
Price CHF139.80
GF Value CHF168.33
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medacta Group Research & Development?

Medacta Group XSWX:MOVE +1.30% 93 Research & Development is CHF22.0 Mil as of Dec. 2025. GuruFocus rates XSWX:MOVE with a GF Score™ of 93/100 and a GF Value™ of CHF168.33 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medacta Group's Research & Development for the six months ended in Dec. 2025 was CHF11.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was CHF22.0 Mil.

Medacta Group  (XSWX:MOVE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medacta Group Research & Development Related Terms

Medacta Group Research & Development Historical Data

* Premium members only.

The historical data trend for Medacta Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group Research & Development Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.77 16.01 19.16 19.97 21.95

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.12 9.88 10.38 10.94 11.07
XSWX:MOVE
93GF Score
Medacta Group SA XSWX:MOVE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF22.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF22.0 Mil mean?
Medacta Group (XSWX:MOVE) has a Research & Development of CHF22.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Medacta Group and its competitors.
Is Medacta Group's Research & Development too high?
Medacta Group's current Research & Development is CHF22.0 Mil. Overall, Medacta Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Research & Development compare to ABT and SYK?
Medacta Group's Research & Development of CHF22.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medacta Group and its competitors. Medacta Group's current Research & Development is CHF22.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (XSWX:MOVE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF168.33, compared to a current price of CHF139.80 — trading 16.9% below its estimated fair value. The current Research & Development is CHF22.0 Mil. Medacta Group's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medacta Group (XSWX:MOVE), the current Research & Development is CHF22.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (XSWX:MOVE) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of CHF139.80 is trading 16.9% below its estimated GF Value™ of CHF168.33. GuruFocus considers Medacta Group to be Modestly Undervalued.

Key valuation signals for XSWX:MOVE:

  • Research & Development: CHF22.0 Mil
  • GF Value™: CHF168.33 vs. price of CHF139.80 (16.9% below fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the XSWX:MOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medacta Group Business Description

Other Exchanges MOVEz:UK0A05:UK6MD:Germany
Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
93GF Score

Get the complete analysis for XSWX:MOVE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF139.80
Price
CHF168.33
GF Value